Determining the minimal important difference of EQ-5D-5 L utility values in CIDP patients using data from a large clinical trial.

What was studied

This study used data from ADHERE, a large trial in CIDP. CIDP is a rare autoimmune disorder with limb weakness and sensory problems. In stage A, 322 people got efgartigimod. The study aimed to find the smallest change in a quality-of-life score that matters. The score is called EQ-5D-5 L.

What they found

The smallest important change was 0.11 by one method. Other methods gave 0.14, 0.10, 0.10 and 0.14. In the extension, 188 people were assessed by week 12. Most people in the extension reached the 0.11 level.

What it means for patients

The authors say the 0.11 value fits with figures from other illnesses. It can help in reading score changes in future studies. They say most people in the extension reached this level. They read this as lasting quality-of-life gains with efgartigimod.

Why it is not certain yet

Estimates ranged from 0.10 to 0.14 across the methods. The extension result covers 188 people at week 12. The abstract names no comparison group for the extension. The abstract does not say how score changes feel in daily life. The abstract says results rest on several different methods.

Source

Determining the minimal important difference of EQ-5D-5 L utility values in CIDP patients using data from a large clinical trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.